FIGURE 2.
Kaplan‐Meier estimate of ARIA‐E risk in subjects receiving 10 mg/kg biweekly lecanemab in the Study 201 OLE for the (A) overall ole population and the (B) ApoE4 carriers subgroup.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.